Abstract
Lipid control is a key pillar of secondary prevention in patients with atherosclerotic cardiovascular disease (ASCVD). Prior analyses have shown suboptimal use of high intensity statins, even among the highest risk patients with ASCVD (e.g., diabetes, prior MI). We surveyed patients with ASCVD and
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
